Shanghai Junshi Biosciences (SHSC:1877) - Hisse Senedi Fiyatı, Haberler ve Analizler

1877 Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Shanghai Junshi Biosciences Co, Ltd, Çin Halk Cumhuriyeti'nde onkoloji, metabolik, otoimmün, nörolojik, sinir sistemi ve bulaşıcı hastalıkların terapötik alanlarında çeşitli ilaçların keşfi, geliştirilmesi ve ticarileştirilmesi ile uğraşmaktadır.

Şirket hakkında

1877 temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Gelirin yılda 25.55% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Shanghai Junshi Biosciences Co., Ltd. Rakipler

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$44.0b

InnoCare Pharma

SEHK:9969

HK$14.5b

CanSino Biologics

SEHK:6185

HK$10.6b

3SBio

SEHK:1530

HK$14.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Shanghai Junshi Biosciences
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$14.42
52 Haftanın En Yüksek Seviyesi	HK$24.60
52 Haftanın En Düşük Seviyesi	HK$9.17
Beta	0.35
11 Aylık Değişim	6.19%
3 Aylık Değişim	22.20%
1 Yıllık Değişim	-27.25%
33 Yıllık Değişim	-63.17%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-83.95%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	1877	HK Biotechs	HK Pazar
7D	-0.3%	-0.1%	-0.9%
1Y	-27.2%	-3.5%	17.3%

Getiri vs. Endüstri: 1877 geçen yıl % 16.7 oranında getiri sağlayan Hong Kong Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 1877 geçen yıl % 19.7 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 1877's price volatile compared to industry and market?
1877 volatility
1877 Average Weekly Movement	11.8%
Biotechs Industry Average Movement	10.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.3%

İstikrarlı Hisse Senedi Fiyatı: 1877 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 1877 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2012	2,532	Cong Li	www.junshipharma.com

Bir biyofarmasötik şirketi olan Shanghai Junshi Biosciences Co., Ltd, Çin Halk Cumhuriyeti'nde onkoloji, metabolik, otoimmün, nörolojik, sinir sistemi ve bulaşıcı hastalıkların terapötik alanlarında çeşitli ilaçların keşfi, geliştirilmesi ve ticarileştirilmesi ile uğraşmaktadır. Şirket 2012 yılında kurulmuştur ve merkezi Çin Halk Cumhuriyeti'nin Şanghay kentindedir.

Shanghai Junshi Biosciences Co., Ltd. Temel Bilgiler Özeti

Shanghai Junshi Biosciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
1877 temel i̇stati̇sti̇kler
Piyasa değeri	HK$30.12b
Kazançlar(TTM)	-HK$2.11b
Gelir(TTM)	HK$1.77b

8.0x

P/S Oranı

-6.7x

F/K Oranı

1877 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
1877 gelir tablosu (TTM)
Gelir	CN¥1.62b
Gelir Maliyeti	CN¥565.18m
Brüt Kâr	CN¥1.05b
Diğer Giderler	CN¥2.98b
Kazançlar	-CN¥1.93b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Oct 29, 2024

Hisse başına kazanç (EPS)	-1.96
Brüt Marj	65.09%
Net Kâr Marjı	-119.28%
Borç/Özkaynak Oranı	38.5%

1877 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

1877 Stoklara Genel Bakış

Ödüller

Risk Analizi

Shanghai Junshi Biosciences Co., Ltd. Rakipler

SEHK:6990

HK$44.0b

SEHK:9969

HK$14.5b

SEHK:6185

HK$10.6b

SEHK:1530

HK$14.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab

Second quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.46 loss in 2Q 2023)

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Recent updates

Shanghai Junshi Biosciences Co., Ltd. Announces the Approval of New Drug Application for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Receives Approval by the European Commission for Marketing of Toripalimab

Second quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.46 loss in 2Q 2023)

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma

Shanghai Junshi Biosciences Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug Application for WJ47156 Tablets

Shanghai Junshi Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Shanghai Junshi Biosciences Co., Ltd. Receives the Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

First quarter 2024 earnings released

Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥2.32 loss per share (vs CN¥2.60 loss in FY 2022)

Full year 2023 earnings released: CN¥2.28 loss per share (vs CN¥2.60 loss in FY 2022)

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List

Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

New minor risk - Profitability

Third quarter 2023 earnings released: CN¥0.42 loss per share (vs CN¥0.75 loss in 3Q 2022)

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Second quarter 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.56 loss in 2Q 2022)

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint

First quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥0.44 loss in 1Q 2022)

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China

Now 26% undervalued

Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116

Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab